Study # IOV-LUN-202

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Study Status:

Enrolling

Treatment Agent:

Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab

Description

Short Title: IOV-LUN-202

This study is to evaluate the efficacy of LN-145 in patients with metastatic NSCLC without an actionable driver mutation who have disease progression on or following a single line of approved systemic therapy consisting of combined immune checkpoint inhibitor(s) (CPI[s]) + chemotherapy ± bevacizumab.

Cohort 1, Cohort 2, and Cohort 4 are open:

Cohort 1: Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1), ie, tumor proportion score (TPS) <1%, prior to ICI treatment and patients with no available historical TPS 

Cohort 2: Patients whose tumors expressed PD-L1 (TPS ≥1%) prior to ICI treatment 

Cohort 4: Patients, regardless of tumor PD-L1 expression status prior to ICI treatment, who had pre-progression tumor harvest 

Resources and Links

National Clinical Trial Identified Number: NCT03645928

Information and next steps

Disease:

  • Non-Small Cell Lung Cancer

Study Phase:

II

Physician Name:

Department:

Ask a Question